New Data Show Decline in Drug Overdose Deaths

From the Centers for Disease Control and Prevention

From 2017-2018, overall overdose death rates decreased by 4.1 percent. Death rates involving heroin dropped by 4 percent and prescription opioid overdose deaths decreased by 13.5 percent.

“Decreases in overdose deaths involving prescription opioids and heroin reflect the effectiveness of public health efforts to protect Americans and their families,” said CDC Director Robert R. Redfield, M.D. “While we continue work to improve those outcomes, we are also addressing the increase in overdose deaths involving synthetic opioids. We must bring this epidemic to an end.”

The bad news: Death rates involving synthetic opioids – excluding methadone – increased by 10 percent in the same period.

These numbers from a CDC analysis of the latest available drug overdose death data from the Morbidity and Mortality Weekly Report, which analyzes changes in age-adjusted overdose death rates by demographic characteristics, county urbanization levels, U.S. Census region and state. From 19992018, more than 750,000 Americans died from drug overdoses.

“To sustain decreases and continue to prevent and respond to drug overdoses, specifically those involving synthetic opioids, it is critical to have a coordinated response,” said Debra Houry, M.D., M.P.H., director of CDC’s National Center for Injury Prevention and Control. “Medical personnel, emergency departments, public health and public safety officials, substance abuse treatment providers, community-based organizations, and members of the community all play a role in addressing this complex and fast-moving epidemic.”

Synthetic Opioid Deaths

Synthetic opioids were involved in 31,335 overdose deaths, nearly half of all overdose deaths in 2018. This is likely due to the illicitly manufactured fentanyl. The four states with the highest increases were Arizona, California, Washington and Missouri.

“Opioid overdoses decreased from 2017 to 2018 but still remain high. Efforts must be strengthened to maintain and accelerate decreases in deaths involving prescription opioids and heroin and to prevent continued increases in overdose deaths involving synthetic opioids,” said Nana Wilson, Ph.D., epidemiologist at CDC and lead author of this MMWR study. An Evolving Crisis

Efforts to improve opioid prescribing practices have increased and may have contributed to decreases in prescription opioid-involved overdose deaths. Drops in heroin-involved deaths may be attributable to reductions in the number of people initiating heroin use and shifts from a heroin-based market to a fentanyl-based market, as well as increased treatment for people using heroin and more access to naloxone.

CDC continues to work closely with other federal agencies to support the U.S. Department of Health and Human Services’ Five-point Strategy to prevent and respond to drug overdoses, specifically those involving opioids. The strategy provides better treatment, better data, better research, increased access to naloxone and better pain management.

CDC is working with states, territories, and cities and counties across the country to continue surveillance and prevention efforts. These efforts are to help inform and to sustain decreases and prevent continued increases through Overdose Data to Action, a three-year cooperative agreement through which CDC funds health departments in 47 states, Washington, D.C., two territories, and 16 cities and counties for surveillance and prevention efforts.

This report also reinforces the continued need for response strategies, including expanding the distribution of naloxone for overdose reversal, increasing the provision of medication-assisted treatment, enhancing public health and public safety partnerships, and enhancing linkage to treatment and harm reduction services. A comprehensive, multisectoral surveillance, prevention, and response approach remains critical for sustaining and expanding preliminary successes in reducing opioid-involved overdose deaths.

FLORIDA PHARMACY ASSOCIATION 131st ANNUAL MEETING AND CONVENTION July 7-11, 2021 Sawgrass Marriott Golf Resort ♦ Ponte Vedra Beach, Florida Poster Session: Friday, July 9, 2021 ♦ 11:00AM-1:00PM COST $ONE DAY REGISTRATION

The FPA Poster Presentations are open to PHARMACISTS, RESIDENTS, STUDENTS, AND TECHNICIANS. Complete and submit this COVERSHEET for each abstract submission. Submissions must be received no later than Friday, May 7, 2021. Abstracts will NOT be accepted after this date. Mail or E-mail this application along with the abstract submission to:

PLEASE TYPE

Contact Information: Tian Merren Owens, MS, PharmD, Director of Continuing Education Florida Pharmacy Association 610 N. Adams Street Tallahassee, FL 32301 tmerren@pharmview.com

Presenter's Name: _______________________________________________________________________________ □ Pharmacist □ Resident □Student □ Technician

Address: ________________________________________________________________________________________

City, State, Zip: ___________________________________________________________________________________

Telephone No: _____________________E-Mail Address: _________________________________________________

College of Pharmacy: _____________________________________________________________________________

Abstract Title: ____________________________________________________________________________________

Poster Type: □ Basic Science Research □ Best Practice

□Clinical Research

□Literature Review

□Translational Research (Basic Science and Clinical Research)

Primary Author: __________________________________________________________________________________ (Presenter will be notified by mail of acceptance).

Co-Author(s): ____________________________________________________________________________________

Awards: Posters will be eligible for 1st, 2nd, and 3rd place prizes to be presented at Convention. (Only one prize is given for each winning poster)

ABSTRACT FORMAT

The abstract form submitted should be the equivalent of one page. The abstract should include: Title (Include authors’ names and name of College of Pharmacy), Purpose, Methods, Results, and Conclusions. Abstracts will not be accepted if it is not in this format. Do not include figures or graphs. Please direct all questions and concerns to: Tian Merren Owens ♦ (850) 222-2400 ext. 120 ♦ tmerren@pharmview.com

“I’M ALWAYS WATCHING OUT FOR MY PATIENTS,

BUT WHO’S WATCHING OUT FOR ME?”

WE ARE.

We are the Alliance for Patient Medication Safety (APMS), a federally listed Patient Safety Organization.

Our Pharmacy Quality Commitment (PQC) program:

• Helps you implement and maintain a continuous quality improvement program • Offers federal protection for your patient safety data and your quality improvement work • Assists with quality assurance requirements found in network contracts,

Medicare Part D, and state regulations • Provides tools, training and support to keep your pharmacy running efficiently and your patients safe